Moving forward with innovative treatments for cardiovascular diseases
Vericel is dedicated to treating patients with severe, chronic cardiovascular diseases through the use of multicellular therapy expanded from the patient’s own bone marrow. In keeping with our mission and values, we use rigorous scientific methods to meet our ultimate goal of treating human disease and relieving human suffering. A necessary part of that process is conducting clinical trials. Vericel currently is in clinical development for two cardiovascular diseases, critical limb ischemia (CLI) and dilated cardiomyopathy (DCM).
- CLI Clinical Trials: We currently have one clinical trial for critical limb ischemia in Phase 3, and our Phase 2 clinical trial is complete. The Phase 3 trial is active and currently enrolling patients. Learn more about CLI clinical trials.
- DCM Clinical Trials: We completed two Phase 2a clinical trials for dilated cardiomyopathy. Learn more about DCM clinical trials.
What is a clinical trial?
To learn more about clinical trials, visit ClinicalTrial.gov, a registry of federally and privately supported clinical trials conducted in the United States and around the world, or contact us with questions about our clinical development process.
Clinical Development Pipeline